Calgary, AB, November 20, 2000 --- Oncolytics Biotech Inc (TSE:ONC)
Dr. Brad Thompson, President & Chief Executive Officer of Oncolytics Biotech Inc. (TSE:ONC) hosted a conference call today to explain the significance and impact of the company's licensing agreement for veterinary use with Pfizer Inc. announced earlier today.

There is a post-view facility, featuring a recording of the conference call available from 10:30 am Calgary time on Monday, November 20 through to end of business on Friday, November 25, 2000 by dialing 1-800-408-3053 and using the following access code 610017#

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.